Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor (ab141083)
Key features and details
- Potent HMG-CoA reductase inhibitor
- CAS Number: 134523-03-8
- Purity: > 99%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor -
製品の詳細
Potent HMG-CoA reductase inhibitor -
精製度
> 99% -
CAS 番号
134523-03-8 -
構造式
製品の特性
-
体系名
(βR,δR)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt -
分子量
577.68 -
分子式
C33H34FN2O5.0.5Ca -
PubChem 登録番号
60822 -
保存方法
Store at -20°C. It is important to note that this product is reported to be light sensitive. Store In the Dark. Store under desiccating conditions. -
溶解性
Soluble in DMSO to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
[Ca+2].O[C@H](CCn1c(c(c(c1C(C)C)C(=O)Nc2ccccc2)c3ccccc3)c4ccc(F)cc4)C[C@@H](O)CC([O-])=O.[O-]C(=O)C[C@H](O)C[C@H](O)CCn4c(c1ccc(F)cc1)c(c2ccccc2)c(C(=O)Nc3ccccc3)c4C(C)C -
由来
Synthetic
-
研究分野
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
- Orphan Nuclear Receptors
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Nucleotide metabolism
- Molecular processes
- Mitochondrial transcription
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab141083の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab141083, Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor
-
ab90529 staining cytochrome C in HepG2 cells treated with atorvastatin hemicalcium salt (ab141083), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of atorvastatin hemicalcium salt, as described in literature.
The cells were incubated at 37°C for 4 hours in media containing different concentrations of ab141083 (atorvastatin hemicalcium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (0)
ab141083 は論文での使用が確認できていません。